Mufaddal Hasan Kathawala

Mr. Mufaddal Hasan Kathawala


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
HKHari P. Kandagatla
Hari P. Kandagatla
MKMufaddal Hasan Kathawala
Mufaddal Hasan Kathawala
ASAmber Syed
Amber Syed
TVTatjana Verbić
Tatjana Verbić
AAAlex Avdeef
Alex Avdeef
ASAbu T. M. Serajuddin
Abu T. M. Serajuddin

2 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ITIgor A. Topalović
Igor A. Topalović
Olivera MarkovićOlivera Marković
Olivera Marković
MPMilos Pesic
Milos Pesic
MKMufaddal Hasan Kathawala
Mufaddal Hasan Kathawala
MKMartin Kuentz
Martin Kuentz
TVTatjana Verbić
Tatjana Verbić
Background/Objectives: Clofazimine (CFZ) is a Biopharmaceutics Classification System (BCS) II drug introduced in the US market in 1986 for the treatment of leprosy. However, CFZ was later withdrawn from the market due to its extremely low aqueous solubility and low absorption. In the literature, the intrinsic solubility of CFZ has been estimated to be <0.01 μg/mL, and solubilities of its different salt forms in simulated gastric and intestinal fluids are 10 mg/mL in the presence of 5 M glutaric acid could be called supersolubilization when compared to the intrinsic solubility of the basic drug. Such an increase in CFZ solubility and the conversion of the glutarate adduct to an amorphous state are being exploited to develop rapidly dissolving dosage forms.

27 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MKMufaddal Hasan Kathawala
Mufaddal Hasan Kathawala
ASAbu T. M. Serajuddin
Abu T. M. Serajuddin
HKHari P. Kandagatla
Hari P. Kandagatla
AAAlex Avdeef
Alex Avdeef
MKMartin Kuentz
Martin Kuentz
TVTatjana Verbić
Tatjana Verbić
Clofazimine (CFZ) is an essential drug listed on the World Health Organization's (WHO) Model List of Essential Medicines, but it is extremely water-insoluble and has significant dissolution and bioavailability issues, and presumably for these reasons, its only commercially available formulation, Lamprene®, was withdrawn from the US market by its manufacturer. In this investigation, we developed amorphous solid dispersions (ASDs) of CFZ using hot-melt extrusion (HME) to increase its dissolution rate. However, the process was challenging because CFZ has a high melting point of 224 °C, requiring high processing temperatures, at which the drug and the polymer used could degrade. Moreover, dissolution of CFZ from ASDs was low and incomplete. These issues were resolved by the interaction of the basic drug with glutaric acid (GA) using the acid-base supersolubilization (ABS) principle, enabling HME at a much lower temperature of 120 °C and increasing drug dissolution. The final ASDs consisted of a mixture of CFZ (10% w/w), glutaric acid (11% w/w), poloxamer 407 (10% w/w), and either Kollidon® VA64 or HPMCAS-LG (69% w/w). The dissolution of 5-mg and 50-mg doses of the formulations with both polymers was evaluated in 250 mL of fed-state intestinal fluid (FeSSIF-V2, pH 5.8) over 2 h. While the 50-mg dose did not fully dissolve under these conditions (40%), the 5-mg dose did (100%). It is postulated that the bioavailability of CFZ would be much higher from new ASDs, thereby reducing the dose.